

## Hernández-Sánchez A, Montojo-Guillén C.

Pharmacy department. Getafe University Hospital. Madrid. Spain.

## **OBJECTIVES**

To **DESCRIBE AND TO ASSESS THE QUALITY RISK** of different prepared sterile products (PSPs) in the hospital pharmacy departments and **PRIORITIZE THE PREVENTATIVE MEASURES IMPLEMENTATION**.



She FAILURE MODE AND EFFECTS ANALYSIS (FMEA): a procedure to identify and reduce/prevent failures in processes and products.

& Three FAILURE MODES (FM) were considered: COMPOUNDING (C), PACKAGING (P) and STERILITY (S).

b Every FM was evaluated for OCURRENCE (O), SEVERITY (S) and DETECTION (D), which value guidelines are shown below:

	VALUE GUIDELINES							
	OCURRENCE (O)	SEVERITY (G)	DETECTION (D)					
9 or 10	Very likely to occur	The effect on the scope renders end item unusable.	There is no detection method (DM) available or known that will provide an alert with enough time to plan for a contingency.					
7 or 8	Will probably occur	The effect on the scope changes the output of the project and it may not be usable to client.	DM is unproven or unreliable; or effectiveness of detection method is unknown to detect in time.					
5 or 6	Equal chance of occurring or not	The effect on the scope changes the output of the project and it will require client approval.	DM has medium effectiveness					
3 or 4	Probably will not occur	The effect on the scope is minor but requires an approved scope change internally and maybe with the client.	DM has moderately high effectiveness.					
1 or 2	Very unlikely	Changes are not noticeable.	DM is highly effective and it is almost certain that the risk will be detected with adequate time.					
		0						

## ♣ RISK PRIORITY NUMBER (RPN) = O × G × D.

b The TOTAL SCORE for each PSP is the sum of the RPN of each FM.

RESULIS										
		PSP	FM	G	0	D	RPN			
TOTAL SCORE	Risk assessment	ANALGESIA- ANESTHESIA	C	8	3	1	24			
≤ 100	Low risk preparation		P	10	3	1	30			
>100	High risk preparation		S	8	3	9	72			
		ANESTIESIA	3	0	1	TOTAL	126			
	rile products studied except	CYTOSTATICS	С	10	3	8	240			
	otal score values above 100,		Р	5	3	4	60			
	re considered as high risk		S	7	1	9	63			
preparations.						TOTAL	363			
The cytostatics o	ompounding has the highest	PARENTERAL NUTRITION	С	8	2	7	112			
	ntails the highest quality risk		Р	8	1	1	8			
for patients.	<b>o</b> 1 <i>y</i>		S	8	1	7	56			
						TOTAL	176			
		ANTIBIOTICS	С	2	2	4	16			
			Р	4	2	5	40			
			S	2	1	9	18			
						TOTAL	74			
CONCLUSIONS										

DEOLU TO

## 1. The cytostatics compounding entails the highest quality risk for patients, therefore our efforts will be focused primarily on these products.

2. After the study, we possess reference values for quality risk comparisons in different situations and circumstances within the same process.

3. We are able to evaluate the effect of preventative measures.